Published in J Immunol on July 15, 2006
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology (2012) 0.93
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol (2010) 0.90
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol (2008) 0.90
CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. J Immunol (2014) 0.88
Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology (2013) 0.88
Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol (2012) 0.87
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells. PLoS One (2013) 0.81
New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Clin Cancer Res (2015) 0.76
Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer. Leukemia (2015) 0.76
Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function. Immunology (2015) 0.76
Gain-of-function experiments on H7N9. Science (2013) 3.67
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell (2009) 2.41
Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood (2007) 2.37
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity (2004) 2.13
Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol (2006) 1.98
Antigen bias in T cell cross-priming. Science (2004) 1.82
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
The cancer antigenome. EMBO J (2012) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science (2009) 1.70
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol (2009) 1.50
Adoptive transfer of T-cell immunity. Trends Immunol (2002) 1.50
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
Memory CD8+ T cells require CD28 costimulation. J Immunol (2007) 1.45
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol (2010) 1.42
Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection. Virology (2005) 1.40
An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions. J Exp Med (2003) 1.40
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39
Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. J Virol (2010) 1.34
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods (2008) 1.28
Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. J Immunol (2006) 1.26
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24
MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24
Inflammation-induced interstitial migration of effector CD4⁺ T cells is dependent on integrin αV. Nat Immunol (2013) 1.24
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
Protection against lethal influenza with a viral mimic. J Virol (2013) 1.18
Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol (2009) 1.16
Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 1.14
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol (2013) 1.13
Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol (2009) 1.12
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11
Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood (2009) 1.11
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2011) 1.11
Early intrahepatic accumulation of CD8+ T cells provides a source of effectors for nonhepatic immune responses. J Immunol (2007) 1.11
Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol (2007) 1.10
Collagen distribution and expression of collagen-binding alpha1beta1 (VLA-1) and alpha2beta1 (VLA-2) integrins on CD4 and CD8 T cells during influenza infection. J Immunol (2007) 1.10
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. J Exp Med (2006) 1.07
Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1. J Immunol (2010) 1.07
Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection. Virology (2004) 1.07
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 1.06
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03
Requirements for effective antitumor responses of TCR transduced T cells. J Immunol (2008) 1.02
CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine (2011) 1.02
CD8+ T cell tolerance and cancer immunotherapy. J Immunother (2003) 1.01
Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01
Specificity and affinity motifs for Grb2 SH2-ligand interactions. Proc Natl Acad Sci U S A (2002) 1.01
The descent of memory T cells. Ann N Y Acad Sci (2011) 1.01
High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00
TCR repertoires of intratumoral T-cell subsets. Immunol Rev (2014) 1.00
The alpha1beta1 integrin and TNF receptor II protect airway CD8+ effector T cells from apoptosis during influenza infection. J Immunol (2007) 1.00
Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells. Hum Immunol (2005) 0.99
TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother (2009) 0.99
Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest (2013) 0.99
The bone marrow functions as the central site of proliferation for long-lived NK cells. J Immunol (2012) 0.97
Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol (2004) 0.97
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2005) 0.97
Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults. Vaccine (2006) 0.97
In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol (2007) 0.96
Class I major histocompatibility complexes loaded by a periodate trigger. J Am Chem Soc (2009) 0.95
Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors. J Immunol (2011) 0.95
An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol (2008) 0.94
The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials (2013) 0.94
Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine (2008) 0.94
Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol (2009) 0.92
PA28 and the proteasome immunosubunits play a central and independent role in the production of MHC class I-binding peptides in vivo. Eur J Immunol (2011) 0.92
Dynamic expression of the Robo ligand Slit2 in bone marrow cell populations. Cell Cycle (2012) 0.92
Platelets present antigen in the context of MHC class I. J Immunol (2012) 0.91
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology (2002) 0.90
B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine (2009) 0.90
T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol (2011) 0.90
Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol (2013) 0.89
The impact of self-tolerance on the polyclonal CD8+ T cell repertoire. J Immunol (2004) 0.88